Daiichi Sankyo Co., Ltd.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 2005-09-28
- Employees
- 18.7K
- Market Cap
- -
Clinical Trials
340
Active:34
Completed:230
Trial Phases
6 Phases
Early Phase 1:1
Phase 1:99
Phase 2:40
+3 more phases
Drug Approvals
13
NMPA:13
Drug Approvals
Mirogabalin Besilate Tablets
- Product Name
- 德力静
- Approval Number
- 国药准字HJ20240066
- Approval Date
- Jun 28, 2024
NMPA
Mirogabalin Besilate Tablets
- Product Name
- 德力静
- Approval Number
- 国药准字HJ20240067
- Approval Date
- Jun 28, 2024
NMPA
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (253 trials with phase data)• Click on a phase to view related trials
Phase 1
99 (39.1%)Phase 3
67 (26.5%)Phase 2
40 (15.8%)Not Applicable
39 (15.4%)phase_1_2
3 (1.2%)Phase 4
3 (1.2%)Early Phase 1
1 (0.4%)phase_2_3
1 (0.4%)First-in-human (FIH) Study of DS-1471a in Subjects with Advanced Solid Tumors
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Daiichi Sankyo Co. Ltd.
- Target Recruit Count
- 19
- Registration Number
- 2024-517984-21-00
- Locations
- 🇺🇸
Florida Cancer Specialist, Sarasota, Florida, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇯🇵National Cancer Center Hospital East, Chiba, Japan
Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia
Completed
- Conditions
- Gastric Cancer
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT05606094
- Locations
- 🇨🇳
Sichuan Cancer Hospital, Chengdu, China
🇨🇳Sun Yat-sen University Cancer Center, Guangdong, China
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, China
Study of VN-0200 in Japanese Healthy Adults and Elderly Subjects
Phase 1
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT04914520
- Locations
- 🇯🇵
Medical Corporation Association Shinanokai Shinanozaka Clinic, Shinjuku-Ku, Tokyo, Japan
Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects
Phase 1
Completed
- Conditions
- Covid19
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2022-08-30
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 142
- Registration Number
- NCT04821674
- Locations
- 🇯🇵
SOUSEIKAI Hakata Clinic, Hakata, Fukuoka, Japan
Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects
Phase 1
Completed
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT04818398
- Locations
- 🇯🇵
Medical Corporation Heishinkai OPHAC Hospital, Osaka, Japan
- Prev
- 1
- 2
- 3
- 4
- 5
- 15
- Next
News
No news found